These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. Saxena S; Wang D; Bystritsky A; Baxter LR J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572 [TBL] [Abstract][Full Text] [Related]
6. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Carpenter LL; McDougle CJ; Epperson CN; Price LH Drug Saf; 1996 Aug; 15(2):116-34. PubMed ID: 8884163 [TBL] [Abstract][Full Text] [Related]
7. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469 [TBL] [Abstract][Full Text] [Related]
8. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders]. Nakamae T Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889 [TBL] [Abstract][Full Text] [Related]
18. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Dold M; Aigner M; Lanzenberger R; Kasper S Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229 [TBL] [Abstract][Full Text] [Related]